Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
News|Articles|November 11, 2025
Maximizing Productivity and Scalability with Perfusion Technology
Author(s)Samsung Biologics
Perfusion-based upstream processing is redefining the production of biopharmaceuticals. By enabling continuous media exchange, perfusion systems maintain high cell density and cell health over longer periods, delivering higher productivity than traditional fed-batch approaches. The result is greater process efficiency, improved scalability, and broader access to affordable therapies. As Biopharma manufacturers face increasing pressure to accelerate timelines and reduce costs, perfusion technology offers a powerful path forward. This executive summary explores practical strategies for implementation, key process control insights, and real-world case studies demonstrating the advantages of perfusion-based production.
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.